Smart nanoparticles for responsive drug delivery in Diabetes: Advances, Challenges, and future Perspectives

This review evaluates smart nanoparticle systems in diabetes management as drug delivery systems that have changed the way treatments for diabetes have been delivered. Diabetes, which includes both type 1 and type 2 forms, represents a significant challenge to human health worldwide. Traditional methods of treating diabetes include manual insulin injections, which, however, suffer from substantial drawbacks: noncompliance and inaccuracies in doses. Smart nanoparticles that can be engineered to physiologically respond to specific stimuli related to diabetes will be a means for achieving better targeted and controlled release delivery of therapeutic agents. This review gives a broad overview of the classes of nanoparticles being developed: polymeric, inorganic, lipid-based, and hybrid systems used in glucose-responsive insulin delivery and oral insulin formulations. Other innovative applications include introducing nanoparticles as components in theranostic systems, whereby a single treatment and diabetes monitoring can be accomplished through a fusion of therapeutic and diagnostic functions. Other current issues tackled by the review include stability and the large-scale production of such systems while fighting immunity problems. This review is meant to provide an outlook for further improvement through incorporating AI into drug delivery that will offer patient-specific dosing regimens or wearable devices combined with drug nanoparticles, as well as the development of eco-friendly biodegradable nanoparticles. Such developments are a great leap toward more effective and patient-centered diabetes care.